|drug980||Daily Monitoring Wiki||1.00|
|drug1179||Emotional Support Plan Wiki||1.00|
|D002659||Child Development Disorders, Pervasive NIH||0.71|
|D001321||Autistic Disorder NIH||0.58|
|D000067877||Autism Spectrum Disorder NIH||0.50|
There is one clinical trial.
The study is designed as a randomized, placebo-controlled, double blind, multicenter, Phase III trial to compare two COVID-19 treatment regimens in hospitalized adult subjects who are diagnosed with severe and critical COVID 19. Arm A: CD24Fc/Best Available Treatment; Arm B: placebo/ Best Available Treatment. CD24Fc will be administered as single dose of 480 mg via IV infusion on Day 1. Total of 270 subjects will be enrolled and randomized in 1:1 ratio to receive CD24Fc or placebo. All subjects will be treated with the best available treatment. The follow up period is 28 days.
Description: Time to improve in clinical status: the time (days) required from the start of treatment to the improvement of clinical status "severe" to "moderate/mild"; or improvement from "scale 2, 3, or 4" to "scale 5 or higher" based on NIAID ordinal scales.Measure: Improvement of COVID-19 disease status Time: 29 days
Description: Proportion of patients who died or had respiratory failure, defined as the need for mechanical ventilation, ECMO, non-invasive ventilation, or high flow oxygen devices, at Day 29Measure: Proportion of patients who died or had respiratory failure. Time: 29 days
Description: Time for disease progression from NIAID scale 3 or 4 to need to be on invasive mechanical ventilation, or ESMO, or death, or from NIAID scale 2 to death.Measure: Disease progression of COVID-19 Time: 29 days
Description: All cause of deathMeasure: All cause of death Time: 15 days and 29 days
Description: Proportion of clinical relapse, as defined by rate of return to oxygen support for more than 1 day within 29 days from randomization after initial recoveryMeasure: Proportion of clinical relapse Time: 29 days
Description: Conversion rate of clinical status on days 8 (proportion of subjects who changed from NIAID ordinal "scale 3 or 4" to "scale 5 or higher")Measure: Conversion rate of clinical status at Day 8 Time: 8 days
Description: Conversion rate of clinical status on days 15 (proportion of subjects who changed from NIAID ordinal "scale 3 or 4" to "scale 5 or higher")Measure: Conversion rate of clinical status at Day 15 Time: 15 days
Description: The discharge time, calculated after the randomization.Measure: Hospital discharge time Time: 29 days
Description: Duration of mechanical ventilation (IMV, NIV) (days)Measure: Duration of mechanical ventilation Time: 29 days
Description: Duration of pressors (days)Measure: Duration of pressors Time: 29 days
Description: Duration of extracorporeal membrane oxygenation (days)Measure: Duration of ECMO Time: 29 days
Description: Duration of oxygen therapy (oxygen inhalation by high flow nasal cannula or mask) (days)Measure: Duration of high flow oxygen therapy Time: 29 days
Description: Changes of absolute lymphocyte count in peripheral bloodMeasure: Absolute lymphocyte count Time: 29 days
Description: The changes of plasma concentration of D-dimersMeasure: Change of D-dimers Time: 15 and 29 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports